Skip to main content

Rinvoq (upadacitinib) Disease Interactions

There are 8 disease interactions with Rinvoq (upadacitinib):

Major

Upadacitinib (applies to Rinvoq) infections

Major Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral, Tuberculosis -- Latent

Serious and sometimes fatal infections, including opportunistic and reactivation of infections have been reported in patients receiving upadacitinib treatment. It is recommended to avoid the use of upadacitinib in patients with an active, serious infection, including localized infections. Closely monitor patients for the development of signs and symptoms of infection during and after treatment with upadacitinib. Interrupt therapy if a patient develops a new infection or an opportunistic infection and appropriate antimicrobial therapy should be initiated. Treatment with upadacitinib may be resumed once the infection is controlled.

Major

Upadacitinib (applies to Rinvoq) malignancy

Major Potential Hazard, Moderate plausibility. Applicable conditions: History - Skin Cancer, Skin Cancer, Lymphoma, Myeloproliferative Disorder

Malignancies, including non-melanoma skin cancer have been reported with the use of upadacitinib. Consider the risks and benefits of upadacitinib treatment prior to initiating therapy in patients with a known malignancy other than a successfully treated non-melanoma skin cancer or when considering continuing treatment in patients who develop a malignancy. It is recommended to perform periodic skin examination.

Major

Upadacitinib (applies to Rinvoq) thrombosis

Major Potential Hazard, Moderate plausibility. Applicable conditions: Thrombotic/Thromboembolic Disorder, History - Thrombotic/Thromboembolic Disorder

Thrombosis, including deep venous thrombosis, pulmonary embolism, and arterial thrombosis, have occurred in patients treated for inflammatory conditions with Janus kinase inhibitors, including upadacitinib. Prior to using this agent in patients who may be at increases risk for thrombosis, it is recommended to consider the risks and benefits associated with treatment. If symptoms of thrombosis occur, patients should be evaluated promptly and treated appropriately.

Moderate

Upadacitinib (applies to Rinvoq) cytopenias

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts

The use of upadacitinib is associated with an increase incidence of neutropenia, lymphopenia, and anemia. Avoid initiation or interrupt treatment with upadacitinib in patients with low neutrophil counts (i.e., ANC less than 1000 cells/mm3), lymphocyte counts (i.e., less than 500 cells/mm3) and low hemoglobin levels (i.e., less than 8 g/dL). It is recommended to evaluate patients for abnormal blood cell counts at baseline and thereafter according to routine patient management.

Moderate

Upadacitinib (applies to Rinvoq) gastrointestinal perforation

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Diverticula

Gastrointestinal perforation has been reported with the use of upadacitinib. This agent should be used with caution in patients who may be at increased risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis or taking NSAIDs). It is recommended to monitor for new onset abdominal symptoms for early identification of gastrointestinal perforation.

Moderate

Upadacitinib (applies to Rinvoq) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

The use of upadacitinib is not recommended in patients with severe hepatic impairment. No dose adjustment is required in patients with mild or moderate hepatic impairment. Treatment with upadacitinib is associated with increased incidence of liver enzyme elevation. Evaluate baseline liver function and thereafter according to routine patient management. Treatment should be interrupted if drug-induced liver injury is suspected.

Moderate

Upadacitinib (applies to Rinvoq) hyperlipidemia

Moderate Potential Hazard, Moderate plausibility.

Treatment with upadacitinib is associated with increases in lipid parameters, including total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol. Care should be exercised when using this agent in patients with hyperlipidemia. It is recommended to monitor patients after initiation of treatment, and thereafter according to the clinical guidelines and to manage patients accordingly.

Moderate

Upadacitinib (applies to Rinvoq) vaccination

Moderate Potential Hazard, Moderate plausibility.

Use of live, attenuated vaccines during, or immediately prior to, upadacitinib therapy is not recommended. Prior to initiating treatment with upadacitinib, it is recommended that patients be brought up to date with all immunizations, including prophylactic zoster vaccinations, in agreement with current immunization guidelines.

Rinvoq (upadacitinib) drug interactions

There are 406 drug interactions with Rinvoq (upadacitinib)

Rinvoq (upadacitinib) alcohol/food interactions

There is 1 alcohol/food interaction with Rinvoq (upadacitinib)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.